Nuveen’s Cabaletta Bio CABA Stock Holding History

Nuveen’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-434,389	Closed	-$602K	–	3290
2025 Q1	$602K	Hold	434,389	–	–	﹤0.01%	2842
2024 Q4	$986K	Hold	434,389	–	–	﹤0.01%	2719
2024 Q3	$2.05M	Buy	434,389 +272,085	+168%	+$1.57M	﹤0.01%	2399
2024 Q2	$1.21M	Sell	162,304 -35,733	-18%	-$438K	﹤0.01%	2636
2024 Q1	$3.38M	Sell	198,037 -43,750	-18%	-$939K	﹤0.01%	2161
2023 Q4	$5.49M	Buy	241,787 +105,809	+78%	+$1.78M	﹤0.01%	1927
2023 Q3	$2.07M	Buy	135,978 +53,910	+66%	+$737K	﹤0.01%	2280
2023 Q2	$1.06M	Buy	+82,068	New	+$891K	﹤0.01%	2636
2021 Q2	–	Sell	-68,401	Closed	-$759K	–	3383
2021 Q1	$759K	Buy	68,401 +59	+0.1%	+$721	﹤0.01%	2982
2020 Q4	$853K	Buy	68,342 +214	+0.3%	+$2.78K	﹤0.01%	2864
2020 Q3	$738K	Buy	68,128 +22,708	+50%	+$261K	﹤0.01%	2811
2020 Q2	$506K	Buy	45,420 +28,869	+174%	+$221K	﹤0.01%	2892
2020 Q1	$121K	Buy	16,551 +6,194	+60%	+$84.9K	﹤0.01%	3051
2019 Q4	$145K	Buy	+10,357	New	+$123K	﹤0.01%	3099

Other funds holding CABA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Nuveen's CABA Position: Q2 2025 in Review

Nuveen sold out of Cabaletta Bio (CABA) in Q2 2025, closing a stake of 434,389 shares — an estimated $602K sold.

Nuveen first reported a position in CABA in Q4 2019 and held it in 14 quarters. The position peaked at $5.49M in Q4 2023. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2025.

Nuveen reported no remaining Cabaletta Bio position as of Q2 2025 after selling out during the quarter.
Nuveen sold 434,389 Cabaletta Bio shares in Q2 2025, an estimated $602K.
Nuveen first reported a position in Cabaletta Bio in Q4 2019 and held it in 14 quarters.
Nuveen's Cabaletta Bio position peaked at $5.49M in Q4 2023.
86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.